Sign up
Pharma Capital

Pacylex Pharmaceuticals CEO says its drug can eradicate cancers in 5 doses

Pacylex Pharmaceuticals, Inc CEO Michael Weickert sat down with Proactive at the Biotech Showcase in San Francisco.

The company is developing a precision medicine solution for multiple common cancers. Its approach exploits a previously-unknown therapeutic target in cancer and its diagnostic technology identifies those patients who will benefit from the drug, sparing many patients needless treatment.


View full PACY profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.